High-density lipoprotein and prostate cancer: an overview

Area of Science:

• Oncology
• Cardiovascular Science
• Epidemiology

Background:

• Prostate cancer presents a significant health burden in developed nations, characterized by high incidence and mortality rates.
• High-density lipoprotein cholesterol (HDL-C) is emerging as a potential biomarker for prostate cancer risk and patient outcomes.
• Existing research suggests a complex relationship between HDL-C levels and prostate cancer, warranting further investigation.

Purpose of the Study:

• To review and summarize epidemiological findings on the association between HDL-C and prostate cancer.
• To evaluate HDL-C as a potential risk and prognostic factor for prostate cancer.

Main Methods:

• Systematic review and synthesis of existing epidemiological studies.
• Analysis of data linking HDL-C levels to prostate cancer incidence and prognosis.

Main Results:

• Several epidemiological studies indicate that low HDL-C levels are associated with an increased risk of developing prostate cancer.
• Low HDL-C levels have also been identified as a prognostic factor in patients with prostate cancer.
• The overall association between HDL-C and prostate cancer is not yet definitively established.

Conclusions:

• Low HDL-C may serve as a risk and prognostic indicator for prostate cancer.
• The precise mechanisms underlying the association between HDL-C and prostate cancer pathophysiology require further elucidation.
• Integrated epidemiological and experimental research is essential to fully understand the role of HDL-C in prostate cancer.